KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis

FRA:PHI1 • NL0000009538

26.59 EUR
+0.44 (+1.68%)
Last: Feb 18, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

Taking everything into account, PHI1 scores 3 out of 10 in our fundamental rating. PHI1 was compared to 67 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PHI1 have multiple concerns. PHI1 has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • PHI1 had positive earnings in the past year.
  • PHI1 had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
  • Of the past 5 years PHI1 4 years had a positive operating cash flow.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B

1.2 Ratios

  • PHI1's Return On Assets of 3.32% is in line compared to the rest of the industry. PHI1 outperforms 46.27% of its industry peers.
  • PHI1 has a Return On Equity of 8.17%. This is comparable to the rest of the industry: PHI1 outperforms 56.72% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 5.16%, PHI1 is in line with its industry, outperforming 40.30% of the companies in the same industry.
  • PHI1 had an Average Return On Invested Capital over the past 3 years of 3.24%. This is significantly below the industry average of 9.66%.
  • The 3 year average ROIC (3.24%) for PHI1 is below the current ROIC(5.16%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROIC 5.16%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • PHI1 has a Profit Margin (5.02%) which is in line with its industry peers.
  • PHI1's Profit Margin has declined in the last couple of years.
  • The Operating Margin of PHI1 (7.98%) is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of PHI1 has declined.
  • The Gross Margin of PHI1 (45.18%) is worse than 73.13% of its industry peers.
  • PHI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHI1 is destroying value.
  • PHI1 has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PHI1 has more shares outstanding
  • Compared to 1 year ago, PHI1 has a worse debt to assets ratio.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • PHI1 has a debt to FCF ratio of 16.37. This is a negative value and a sign of low solvency as PHI1 would need 16.37 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 16.37, PHI1 is not doing good in the industry: 62.69% of the companies in the same industry are doing better.
  • PHI1 has a Debt/Equity ratio of 0.63. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.63, PHI1 is doing worse than 70.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Altman-Z N/A
ROIC/WACC0.8
WACC6.47%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • PHI1 has a worse Current ratio (1.32) than 61.19% of its industry peers.
  • PHI1 has a Quick Ratio of 1.32. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.94, PHI1 is not doing good in the industry: 65.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.94
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.45% over the past year.
  • Measured over the past years, PHI1 shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.53% on average per year.
  • Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -1.04% in the last year.
  • The Revenue has been growing slightly by 0.59% on average over the past years.
EPS 1Y (TTM)12.45%
EPS 3Y17.92%
EPS 5Y-5.53%
EPS Q2Q%15.25%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%-1.22%

3.2 Future

  • Based on estimates for the next years, PHI1 will show a small growth in Earnings Per Share. The EPS will grow by 7.17% on average per year.
  • Based on estimates for the next years, PHI1 will show a small growth in Revenue. The Revenue will grow by 3.79% on average per year.
EPS Next Y-2.32%
EPS Next 2Y5.02%
EPS Next 3Y13.51%
EPS Next 5Y7.17%
Revenue Next Year2.83%
Revenue Next 2Y3.55%
Revenue Next 3Y4.91%
Revenue Next 5Y3.79%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 17.04, PHI1 is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Earnings ratio of PHI1 indicates a rather cheap valuation: PHI1 is cheaper than 85.07% of the companies listed in the same industry.
  • PHI1 is valuated rather cheaply when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 17.47, PHI1 is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, PHI1 is valued a bit cheaper than 61.19% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.16. PHI1 is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 17.04
Fwd PE 17.47
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHI1 is valued a bit cheaper than the industry average as 70.15% of the companies are valued more expensively.
  • PHI1's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 51.83
EV/EBITDA 12.12
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • PHI1's earnings are expected to grow with 13.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.02%
EPS Next 3Y13.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KONINKLIJKE PHILIPS NV

FRA:PHI1 (2/18/2026, 7:00:00 PM)

26.59

+0.44 (+1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners44.83%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap25.60B
Revenue(TTM)17.83B
Net Income(TTM)895.00M
Analysts73.33
Price Target27.26 (2.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.35
Dividend Growth(5Y)216.55%
DP36.65%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.15%
Min EPS beat(2)14.1%
Max EPS beat(2)22.2%
EPS beat(4)4
Avg EPS beat(4)22.4%
Min EPS beat(4)14.1%
Max EPS beat(4)31.04%
EPS beat(8)4
Avg EPS beat(8)5.12%
EPS beat(12)6
Avg EPS beat(12)7.99%
EPS beat(16)7
Avg EPS beat(16)8.07%
Revenue beat(2)0
Avg Revenue beat(2)-2.61%
Min Revenue beat(2)-2.82%
Max Revenue beat(2)-2.4%
Revenue beat(4)0
Avg Revenue beat(4)-2.29%
Min Revenue beat(4)-2.82%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-2.85%
Revenue beat(12)1
Avg Revenue beat(12)-2.52%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)-1.52%
PT rev (3m)-0.19%
EPS NQ rev (1m)-15.5%
EPS NQ rev (3m)-15.5%
EPS NY rev (1m)-0.33%
EPS NY rev (3m)-0.56%
Revenue NQ rev (1m)3.12%
Revenue NQ rev (3m)3.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.59%
Valuation
Industry RankSector Rank
PE 17.04
Fwd PE 17.47
P/S 1.44
P/FCF 51.83
P/OCF 22.03
P/B 2.34
P/tB N/A
EV/EBITDA 12.12
EPS(TTM)1.56
EY5.87%
EPS(NY)1.52
Fwd EY5.72%
FCF(TTM)0.51
FCFY1.93%
OCF(TTM)1.21
OCFY4.54%
SpS18.52
BVpS11.38
TBVpS-0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number19.99
Profitability
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROCE 7.33%
ROIC 5.16%
ROICexc 6.02%
ROICexgc 20.88%
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
FCFM 2.77%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.24%
ROIC(5y)N/A
ROICexc(3y)3.72%
ROICexc(5y)N/A
ROICexgc(3y)12.84%
ROICexgc(5y)N/A
ROCE(3y)4.62%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.31%
ROICexc growth 3YN/A
ROICexc growth 5Y-4.82%
OM growth 3YN/A
OM growth 5Y-5.59%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Debt/EBITDA 2.72
Cap/Depr 59.38%
Cap/Sales 3.75%
Interest Coverage 5.63
Cash Conversion 45.59%
Profit Quality 55.2%
Current Ratio 1.32
Quick Ratio 0.94
Altman-Z N/A
F-Score7
WACC6.47%
ROIC/WACC0.8
Cap/Depr(3y)53.03%
Cap/Depr(5y)53.41%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.45%
EPS 3Y17.92%
EPS 5Y-5.53%
EPS Q2Q%15.25%
EPS Next Y-2.32%
EPS Next 2Y5.02%
EPS Next 3Y13.51%
EPS Next 5Y7.17%
Revenue 1Y (TTM)-1.04%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%-1.22%
Revenue Next Year2.83%
Revenue Next 2Y3.55%
Revenue Next 3Y4.91%
Revenue Next 5Y3.79%
EBIT growth 1Y15922.2%
EBIT growth 3YN/A
EBIT growth 5Y-5.03%
EBIT Next Year63.55%
EBIT Next 3YN/A
EBIT Next 5Y17.05%
FCF growth 1Y-43.86%
FCF growth 3YN/A
FCF growth 5Y-22.31%
OCF growth 1Y-25.32%
OCF growth 3YN/A
OCF growth 5Y-15.14%

KONINKLIJKE PHILIPS NV / PHI1.DE FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


How profitable is KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 3 / 10.


How financially healthy is KONINKLIJKE PHILIPS NV?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 1 / 10.


Can you provide the dividend sustainability for PHI1 stock?

The dividend rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 0 / 10 and the dividend payout ratio is 36.65%.